Degarelix

And FDA approved hormonal therapy for advanced prostate cancer. Degarelix blocks the action of gonatotropin-releasing hormone (GnRH) receptors and results in suppression of testosterone production. Belongs to a class of drugs called GNRH-antagonists or LHRH-antagonists (Leutinizing hormone-releasing hormone).